Aleksandra V. Solov'YEva

Aleksandra V. Solov'YEva

Auto-generated profile, based on publicly available information

Aleksandra V. Solov'YEva

Ryazan State Medical University named after academician I.P. Pavlov

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2022 in Nauka Molodykh (Eruditio Juvenium)
Verified
Journal Article
Closed access
RURyazan State Medical University
Ryazan State Medical University
ASAleksandra V. Solov’yEva
Aleksandra V. Solov’yEva
TCTat’yAna M. Cherdantseva
Tat’yAna M. Cherdantseva
ACAleksey V. Cheskidov
Aleksey V. Cheskidov
KSKristina A. Shukis
Kristina A. Shukis
INTRODUCTION: Epicardial adipose tissue is usually located on the free wall of the right ventricle, the left ventricular apex, and the atria, but the valvular apparatus of the heart, the interventricular and interatrial septum can be subjected to lipotoxic damage. The accumulation of adipose tissue on the interatrial septum is of particular scientific interest and is described in the literature as lipomatous hypertrophy. AIM: To study the clinical and morphological features of lipomatous hypertrophy of interatrial septum in patients with diseases of the cardiovascular system. MATERIALS AND METHODS: Morphological examination of the hearts of 60 patients (30 men, 30 women), average age 74.6 ± 9.5 years was conducted. Morphometric parameters of the heart muscle and the aorta were evaluated. The studied heart material was stained with hematoxylin-eosin and according to Mallory and was processed by standard histological methods. RESULTS: The causes of death of patients were myocardial infarction, cerebral infarction, postinfarction cardiosclerosis and type 2 diabetes. The analysis of thickness of the interatrial septum in patients of different groups revealed lipomatosis of the interatrial septum in 83% of patients with postinfarction cardiosclerosis, in 80% of patients with myocardial infarction, in 70% with type 2 diabetes, in 66.7% with cerebral infarction. The thickness of the interatrial septum with lipomatous hypertrophy was 1.2 ± 0.12 cm in patients with myocardial infarction, 1.2 ± 0.11 cm in cerebral infarction, 1.2 ± 0.2 cm in postinfarction cardiosclerosis, 1.2 ± 0.15 cm in type 2 diabetes. There were no reliable differences in the thickness of the interatrial septum between the study groups. The correlation was established between the thickness of the interatrial septum with lipomatous alterations and hypertrophy of the anterior wall of the left ventricle (r = 0.7; р < 0.0001), fibrosis of the anterior wall of the left ventricle (r = 0.6; p = 0.03), thickness of epicardial fat (r = 0.5; p = 0.0002), as well as the interrelation with the thickness of the interventricular septum (r = 0.7; p < 0.05). The existence of epicardial fat in individuals with lipomatosis of the interatrial septum positively correlated with the thickness of the interventricular septum (r = 0.5; p = 0.01) and the thickness of the posterior wall of the left ventricle (r = 0.6; p = 0.001). The correlation relationship was also established between the thickness of the interatrial septum with lipomatous alterations and laboratory markers of cardiovascular risk: the level of total cholesterol (r = 0.8; p = 0.01), triglycerides (r = 0.6; p = 0.001), low-density lipoproteins (r = 0.7; p = 0.001). CONCLUSION: Taking into account the interrelations of lipomatous hypertrophy of the interatrial septum identified in the morphological and histological examination, as well as echocardiography data and some biochemical markers, this parameter can be recommended for use in assessment of cardiovascular risk in echocardiography.

3 April 2023 in I.P. Pavlov Russian Medical Biological Herald
Verified
Journal Article
Open access
PDF file
ASAleksandra V. Solov'YEva
Aleksandra V. Solov'YEva
AGArzu Arifovna Gurbanova
Arzu Arifovna Gurbanova
IMIvan A. Maksimtsev
Ivan A. Maksimtsev
OLOksana Yu. Lazareva
Oksana Yu. Lazareva
EMElena A. Maksimtseva
Elena A. Maksimtseva
INTRODUCTION: Myocardial bridging (MB) is considered a benign pathology, however, its existence is often associated with angina pectoris, myocardial infarction, ventricular tachycardia and sudden cardiac death. The clinical significance of MB is determined by the dynamic stenosis of the coronary artery, which depends on the rate and strength of heart contractions and is poorly visualized by instrumental methods, which impairs timely diagnosis and early administration of the adequate treatment. A clinical case of a combined damage to the coronary bed in a 58-year-old patient is presented: MB of the anterior interventricular artery (AIVA) causing dynamically significant narrowing of the tunnel artery and hemodynamically insignificant atherosclerotic lesion of the coronary arteries. MB was typically located in the mid-segment of the AIVA. The diagnosis of the anomaly of the coronary bed was established after coronary angiography: MB of AIVA led to stenosis of the tunnel segment to 80% and was the cause of angina attacks. Stenting of the AIVA with a drug-coated stent was performed. The effectiveness of the stenting can be referred to a peculiar feature of this case, since in the treatment of this pathology the preference is given to myotomy and coronary artery bypass grafting as more effective methods. The follow-up period was 7.5 years; after stenting of the tunnel segment of the AIVA the anginal attacks did not recur. CONCLUSION: The described clinical case demonstrates the role of MB in the development of myocardial ischemia. With timely diagnosis of the coronary blood flow disorders, successful revascularization and adequate pharmacotherapy in accordance with the current clinical recommendations, the prognosis is good.

28 December 2022 in I.P. Pavlov Russian Medical Biological Herald
Verified
Journal Article
Closed access
PDF file
SBSergey G. Bolotin
Sergey G. Bolotin
MZMariya S. Zenina
Mariya S. Zenina
ASAleksandra V. Solov’yEva
Aleksandra V. Solov’yEva
APAlexandr S. Pristupa
Alexandr S. Pristupa
INTRODUCTION: Multiple myeloma (MM) is a disease whose substrate is plasma cells; it is characterized by the production of monoclonal immunoglobulin. Epidemiology of MM in Russia is insufficiently studied. Of interest is a study of dynamics of the main epidemiological parameters of multiple myeloma in the context of a poor epidemiological prognosis for oncological diseases in the Russian Federation and in the world in general. AIM: To analyze the main epidemiological parameters of symptomatic MM in the Ryazan region for 10 years (20102019). MATERIALS AND METHODS: A total of 343 medical records of patients with symptomatic MM were analyzed, of them 146 men (age median 65 years), 197 women (age median 64 years). The patients underwent inpatient treatment in the hematology and chemotherapy department of Ryazan Regional Clinical Hospital from 2010 to 2019. The epidemiological analysis consisted in evaluation of the parameters of the registered morbidity, prevalence and hospital mortality. The criterion for inclusion in the study was the existence of symptomatic MM in the patient. For statistical processing, Microsoft information and analytical system, Office package was used. RESULTS: The highest amount of new cases of MM were identified in 2018 (4.19 per 100,000 population), the lowest in 2012 (1.83 per 100,000 population). In the analyzed period, the number of cases of newly diagnosed MM per year increased by 30.3%. Most patients at the time of diagnosis were in the age group of 6069 years. Morbidity with MM in the age group of 3049 years was comparable in men and women, however, among the patients 50 years women predominated. Over 10 years, the index of MM prevalence in the Ryazan region increased 1.43 times: from 6.71 to 9.6 per 100,000 population, index of hospital mortality from 1.4% to 3.3%. CONCLUSION: The growth of the registered mortality and prevalence of MM in the Ryazan region in 20102019 was identified, which corresponds to the dynamics in other regions of the Russian Federation. Also, during the analyzed period, an increase in hospital mortality of patients with MM was observed in the region.

7 October 2022 in I.P. Pavlov Russian Medical Biological Herald
Verified
Journal Article
Open access
PDF file
ASAleksandra V. Solov’yEva
Aleksandra V. Solov’yEva
LKLudmila Korshunova
Ludmila Korshunova
ESEkaterina Shurpo
Ekaterina Shurpo
ANAnastasia Namestnikova
Anastasia Namestnikova
INTRODUCTION: In recent years, the production and regulation of synthesis of hyaluronic acid in COVID-19 has been actively studied. Hyaluronan plays a significant role in development of severe lung damage in COVID-19 and is a potential therapeutic target the action on which will probably improve prognosis for patients with COVID-19. AIM: To study prospects of using bovhyaluronidaze azoximer in complex treatment of patients with COVID-19 with lung damage at the inpatient stage. MATERIALS AND METHODS: Thirty five patients (6 men and 29 women) aged 58.9 12.9 years hospitalized with COVID-19 infection, were examined. Capillary blood saturation (SpO2) was 80.1 8.6%, the volume of lung damage in X-ray computed tomography (X-ray CT) was 45.1 19.4% on the right and 40.0 19.5% on the left. All the patients received treatment according to the Temporary Guidelines: prevention, diagnosis and treatment of novel coronavirus infection. Ver. 14 (27.12.2021). Besides, as part of complex treatment for COVID-19, bovhyaluronidaze azoximer was administered intramuscularly on the 21.9 6.8th day of illness with a course of 10 injections (once in 3 days). RESULTS: In the course of comprehensive treatment including bovhyaluronidaze azoximer, increase in SpO2 was recorded: in 7 patients ― after 1 injection (4.2 1.7%), in 24 ― after 2 injections (5.4 0.6%), another 4 patients did not show any significant increase in SpO2 after the first two injections. Increase in SpO2 after the 1st injection inversely correlated with age (r = -0.34; p 0.05) and the initial saturation (r = -0.38; p 0.05). Increase in SpO2 after the second injection correlated with the day of illness on which treatment with bovhyaluronidaze azoximer began (r = -0.36; p 0.05). CONCLUSION: Use of bovhyaluronidaze azoximer in complex treatment for COVID-19 with the lung damage at the inpatient stage can be effective in younger patients with more expressed initial reduction of SpO2, and also in case of administration of the drug in the early stages of the disease. The data obtained in the pilot study, dictate the necessity of studying the level of hyaluronic acid in blood of patients with COVID-19 and lung damage and its role in risk stratification of such patients.

16 July 2023 in I.P. Pavlov Russian Medical Biological Herald
Verified
Journal Article
Open access
PDF file
OUOleg M. Uryasyev
Oleg M. Uryasyev
ASAleksandra V. Solov’yEva
Aleksandra V. Solov’yEva
ACAleksey V. Cheskidov
Aleksey V. Cheskidov
AFAnastasiya A. Filimonova
Anastasiya A. Filimonova
ENEkaterina А. Nikiforova
Ekaterina А. Nikiforova
INTRODUCTION: Obesity is one of the leading risk factors for the development of cardiovascular diseases. At present, of the greatest scientific interest are local deposits of adipose tissue as a possible morphological substrate for the development of this group of diseases. Along with the traditional risk factors, one more risk factor for a poor prognosis of cardiovascular disease can be a change in the thickness of the epicardial fat (EF) and of the interatrial septum (IAS) in case of its lipomatosis. AIM: To study the significance of EF and of IAS thickness as markers of cardiovascular risk in coronary heart disease. MATERIALS AND METHODS: The study involved 116 individuals with coronary heart disease (55 men (47%) and 61 women (53%), mean age 68 [61; 72] years). Thickness of EF and IAS was evaluated by the method of echocardiography. The frequency of poor outcomes was evaluated using KaplanMeier method, ROC-curve analysis. The differences were considered statistically significant at p 0.05. RESULTS: In the group of patients with unstable angina, the threshold value of IAS thickness was 0.7 cm (p 0.001), and of EF thickness 0.8 cm (2 = 10.89, p = 0.001), in the group of patients with myocardial infarction 0.7 cm (p 0.001) and 0.8 cm (p 0.001), respectively. In the group of patient with unstable angina, IAS thickness 0.7 cm (2 = 10.3, p = 0.0013) and EF thickness 0.8 cm (2 = 10.89, p = 0.001) demonstrate a poor prognosis in comparison with the parameters below the threshold values. In the group of patients with myocardial infarction, IAS thickness 0.7 cm (2 = 8.4, p = 0.005) and EF 0.8 cm (2 = 9.66, p = 0.0019) demonstrate poor prognosis in comparison with the parameters below the threshold values. CONCLUSION: In unstable angina and myocardial infarction, the value of IAS thickness 0.7 cm (p = 0.0013 and p = 0.005, respectively) and of EF thickness 0.8 cm (p = 0.001 and p = 0.0019, respectively) present a poor prognosis compared to lower values. It is recommended that EF and IAS thickness be determined in echocardiography as an additional marker for a poor prognosis in coronary heart disease.

31 December 2024 in Nauka Molodykh (Eruditio Juvenium)
Verified
Journal Article
Closed access
RURyazan State Medical University
Ryazan State Medical University
OUOleg M. Uryas’yEv
Oleg M. Uryas’yEv
ASAleksandra V. Solov’yEva
Aleksandra V. Solov’yEva
OSOl’gA A. Smaznova
Ol’gA A. Smaznova
EHEmergency Medical Care Hospital
Emergency Medical Care Hospital
ESEkaterina M. Shurpo
Ekaterina M. Shurpo
INTRODUCTION: The clinical picture of COVID-19 has been highly variable since the onset of the pandemic: most patients present with mild symptoms, while others develop severe respiratory failure. It seems relevant to compare subjective and objective manifestations of COVID-19 in hospitalized patients and to evaluate the prognostic significance of clinical, laboratory and radiological characteristics of COVID-19. AIM: To analyze the interrelation between the evidence of subjective and objective data, comorbidity in patients with COVID-19 depending on the outcome of the disease. MATERIALS AND METHODS: The study included 96 patients aged from 25 to 95 years, hospitalized in COVID hospital of City Clinical Emergency Care Hospital of Ryazan from February to May 2022. Patients underwent evaluation of cough and dyspnea intensity on Borg scale, physical examination, laboratory examination, X-ray computed tomography (X-ray CT) of lungs or roentgenography. Depending of the clinical outcome, patients were divided into 2 groups: a group of survivors (68 patients) and a group of deceased (28 patients). Statistical analysis of the data was performed using Statistica 10.0 software package (Stat Soft Inc., USA). RESULTS: The most common complaints on admission were shortness of breath (75%) and general weakness (96.8%). Twenty-four patients indicated absence of dyspnea, while in 19 of them, saturation below 95.0% was recorded. In patients with ‘silent’ dyspnea, X-ray CT revealed statistically significant strong reverse correlation relationships between saturation and lung lesion volume (р < 0.05). Deceased patients had higher subjective evidence of dyspnea and frequency of distant wheezes (р = 0.002 and р < 0.0001, respectively). Overweight, postinfarction cardiosclerosis, chronic heart failure, type 2 diabetes mellitus were more common among deceased patients. Saturation on admission was statistically significantly lower in the group of deceased (р < 0.0001). The first degree of lung damage on X-ray CT was more common in the group of survivors (0.009), the fourth degree of lung damage more commonly occurred in the group of deceased (р = 0.01). In the group of deceased, the hemoglobin level was significantly lower (р = 0,044), and the levels of fibrinogen, lactate dehydrogenase (LDH), urea, glucose, were significantly higher than in the group of survivors. CONCLUSION: When evaluating the severity of the disease in patients with COVID-19, it is necessary to take into account not only the level of laboratory markers, such as LDH, fibrinogen, urea, fasting glycemia, laboratory instrumental test results that evaluate the severity of respiratory failure and spread of the lung tissue damage, but also subjective manifestations of the disease such as higher intensity of dyspnea and distant wheezes. Patients who have reduced saturation with no complaints of dyspnea require increased attention.